The FDA approved ribociclib (Kisqali) for adjuvant treatment of high-risk, hormone receptor-positive, HER2-negative early breastcancer. The FDA approved ribociclib (Kisqali) with an aromatase ...
Opens in a new tab or window The FDA on Tuesday approved ribociclib (Kisqali) in combination with endocrine therapy as adjuvant treatment for early high-risk breastcancer. Already approved in ...
The US FDA has approved Kisqali (ribociclib) for treating early-stage breastcancer in combination with hormone therapy. It targets high-risk HR-positive, HER2-negative stage II and III patients ...
Results that may be inaccessible to you are currently showing.